Encorafenib
Sign in to save this workspacePrimary targets: BRAF · FDA status: FDA Approved
Selectivity scorecard
KISS
98.50
Gini
0.755
CATDS
0.029
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Encorafenib. Strongest target: RAF1 at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RAF1 | 99.7% | 0.3% |
| 2 | BRAF | 98.0% | 2.0% |
| 3 | IRAK1 | 97.5% | 2.5% |
| 4 | ARAF | 97.4% | 2.6% |
| 5 | LIMK2 | 93.9% | 6.1% |
| 6 | GSK3B | 91.5% | 8.5% |
| 7 | LIMK1 | 88.5% | 11.5% |
| 8 | JNK3 | 82.1% | 17.9% |
| 9 | RIPK3 | 76.6% | 23.4% |
| 10 | NLK | 71.3% | 28.6% |
| 11 | JNK1 | 69.9% | 30.1% |
| 12 | JNK2 | 65.6% | 34.4% |
| 13 | ZAK_MLTK | 63.5% | 36.5% |
| 14 | MLK2_MAP3K10 | 62.1% | 37.9% |
| 15 | HIPK4 | 54.2% | 45.8% |
| 16 | P38A_MAPK14 | 53.5% | 46.5% |
| 17 | CK1G2 | 52.6% | 47.4% |
| 18 | TESK2 | 52.3% | 47.7% |
| 19 | PDK2_PDHK2 | 48.5% | 51.5% |
| 20 | MKK6 | 48.4% | 51.6% |
Selectivity landscape
Where Encorafenib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Encorafenib.
Atlas insights for Encorafenib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.863 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.846 |
| SRR1443713 | GTEX | 0.842 |
| SRR12202498 | — | 0.841 |
| SRR1311182 | GTEX | 0.824 |
Annotations
Sign in to read and post annotations.
Loading…